Telix Pharmaceuticals achieved double-digit revenue growth and positive adjusted operating cash flow in FY 2025, with revenue reaching US$803.8 million, a 56% increase year-over-year. The company invested significantly in R&D and strategic acquisitions, resulting in a non-material loss before tax of US$5.3 million, while maintaining a year-end cash balance of US$141.9 million.